Literature DB >> 17016659

Combination of 5-FU and IFNalpha enhances IFN signaling pathway and caspase-8 activity, resulting in marked apoptosis in hepatoma cell lines.

Kazuko Koike1, Akinobu Takaki, Masashi Tatsukawa, Mayumi Suzuki, Hidenori Shiraha, Yoshiaki Iwasaki, Kohsaku Sakaguchi, Yasushi Shiratori.   

Abstract

Interferon (IFN) combined with 5-Fluorouracil (5-FU) treatment has recently been reported to show beneficial effects in patients with advanced hepatocellular carcinoma. IFNalpha is usually provided for this combination therapy. In this study, we investigated the molecular mechanisms of apoptosis induction in hepatoma cell lines with IFNalpha and 5-FU combination therapy from the view point of 5-FU's additive effect on interferon-related signaling pathways. Five hepatoma cell lines (Hep3B, Huh7, HLE, PLC/PRF/5, and HepG2) were tested for apoptosis inducibility by IFNalpha in the absence or presence of 5-FU. Hep3B was the most apoptosis sensitive to IFN plus 5-FU treatment. The JAK/STAT pathway transcriptional factor ISRE was activated more synergistically when 5-FU was added to IFNalpha treatments. Caspase-3, -9, and especially caspase-8 activity was higher with IFN alpha plus 5-FU than IFN or 5-FU alone. Inhibition of caspase-8, -9, c-Jun N-terminal kinase (JNK), phosphatidylinositide 3-kinase (PI3K), and p38 mitogen-activated protein kinase (p38 MAPK) revealed that caspase-8 inhibition was the most effective at decreasing the apoptotic effects of IFN and/or 5-FU. In JAK1 and ISGF3gamma-silenced Hep3B cells, the apoptosis induction and caspase-8 activation levels by IFN, even in combination with 5-FU, were abrogated. In conclusion, caspase-8 is the most important factor that controls IFN and 5-FU-induced apoptosis in hepatoma cell lines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17016659

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

Review 1.  Interferons as inducers of apoptosis in malignant cells.

Authors:  Kevin P Kotredes; Ana M Gamero
Journal:  J Interferon Cytokine Res       Date:  2013-04       Impact factor: 2.607

2.  Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B.

Authors:  Guo-Hua Qiu; Xiaojin Xie; Fang Xu; Xiaohao Shi; Yue Wang; Linhong Deng
Journal:  Cytotechnology       Date:  2014-07-08       Impact factor: 2.058

3.  Adjuvant intraportal venous chemotherapy for patients with hepatocellular carcinoma and portal vein tumor thrombi following hepatectomy plus portal thrombectomy.

Authors:  Li-Jian Liang; Wen-Jie Hu; Xiao-Yu Yin; Qi Zhou; Bao-Gang Peng; Dong-Ming Li; Ming-De Lu
Journal:  World J Surg       Date:  2008-04       Impact factor: 3.352

4.  Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.

Authors:  Daniel Benten; Gunhild Keller; Alexander Quaas; Jorg Schrader; Artur Gontarewicz; Stefan Balabanov; Melanie Braig; Henning Wege; Jurgen Moll; Ansgar W Lohse; Tim H Brummendorf
Journal:  Neoplasia       Date:  2009-09       Impact factor: 5.715

5.  An aggressive approach leads to improved survival in hepatocellular carcinoma patients with portal vein tumor thrombus.

Authors:  De-Xin Lin; Qi-Yu Zhang; Xuan Li; Qi-Wen Ye; Fen Lin; Lin-Li Li
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-26       Impact factor: 4.553

6.  Downregulation of orosomucoid 2 acts as a prognostic factor associated with cancer-promoting pathways in liver cancer.

Authors:  Han-Zhang Zhu; Wei-Jiang Zhou; Ya-Feng Wan; Ke Ge; Jun Lu; Chang-Ku Jia
Journal:  World J Gastroenterol       Date:  2020-02-28       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.